T1	Participants 47 159	patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus
T2	Participants 175 226	36 patients treated in France in the RECORD-1 Trial
T3	Participants 286 376	patients with metastatic renal cell carcinoma (mRCC) typically receive multiple treatments
T4	Participants 414 502	patients previously treated with tyrosine kinase inhibitors (TKI) sunitinib or sorafenib
T5	Participants 561 626	patients with disease progression after a TKI-everolimus sequence
T6	Participants 672 776	patients enrolled in RECORD-1 (Renal Cell Cancer Treatment With Oral RAD001 Given Daily) at French sites
T7	Participants 860 911	patients treated with a TKI-everolimus-TKI sequence
T8	Participants 921 972	Thirty-six patients received a TKI after everolimus
